12:05 PM EDT, 09/19/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)

Edgewise Therapeutics' ( EWTX ) shares surged 55% in recent Thursday trading after the company said EDG-7500, an investigational treatment for cardiomyopathy, was found to be well-tolerated in two early trials.

Results showed that EDG-7500 was well-tolerated in a phase 1 study on healthy subjects and a phase 2 study on patients with obstructive hypertrophic cardiomyopathy with no significant side effects such as changes in the heart's pumping of blood, Edgewise said.

Edgewise said it began dosing patients for a 28-day part of the obstructive ECM trial and initial results are expected in Q1.

Price: 29.63, Change: +10.56, Percent Change: +55.37